Open Access Articles- Top Results for Belinostat


Systematic (IUPAC) name
Clinical data
Trade names Beleodaq
AHFS/ entry
  • US: D (Evidence of risk)
866323-14-0 7pxN
PubChem CID 6918638
ChemSpider 5293831 7pxY
UNII F4H96P17NZ 7pxY
ChEBI CHEBI:61076 7pxY
ChEMBL CHEMBL408513 7pxY
Synonyms PXD101
Chemical data
Formula C15H14N2O4S
318.348 g/mol

Belinostat (PXD101, trade name Beleodaq) is a drug under development by TopoTarget for the treatment of hematological malignancies and solid tumors. It is a histone deacetylase inhibitor.[1]

In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer.[2] Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging.[3] Belinostat has been granted orphan drug and fast track designation by the FDA,[4] and was approved in the US for the use against peripheral T-cell lymphoma. It is not approved in Europe as of August 2014.[5]


  1. ^ Plumb, Jane A.; Finn, Paul W.; Williams, Robert J.; Bandara, Morwenna J.; Romero, M. Rosario; Watkins, Claire J.; La Thangue, Nicholas B.; Brown, Robert (2003). "Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101". Molecular Cancer Therapeutics 2 (8): 721–728. PMID 12939461. 
  2. ^ "CuraGen Corporation (CRGN) and TopoTarget A/S Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference". October 2007. 
  3. ^ Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma, December 2009 
  4. ^ "Spectrum adds to cancer pipeline with $350M deal.". February 2010. 
  5. ^ H. Spreitzer (4 August 2014). "Neue Wirkstoffe – Belinostat". Österreichische Apothekerzeitung (in German) (16/2014): 27. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.